After Arrowhead (ARWR) Pharmaceuticals released initial Phase 1/2a data for ARO-INHBE and ARO-ALK7, with both programs demonstrating significant fat reduction, H.C. Wainwright says these data provide “a significant validation” of TRiM, Arrowhead’s RNA interference platform, and de-risk Arrowhead’s obesity franchise. The firm reiterates its Buy rating on Arrowhead shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR: